DiaMedica Therapeutics (DMAC) Receivables - Net (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Receivables - Net for 10 consecutive years, with $244000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net rose 51.55% year-over-year to $244000.0; the trailing twelve-month figure through Jun 2026 stood at $244000.0 (up 51.55% YoY), and the FY2025 full-year result was $258000.0, up 9.32% from the prior year.
• Receivables - Net eased to $244000.0 in Q2 2026 per DMAC's latest filing, from $301000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $399000.0 in Q1 2024 and bottomed at $57000.0 in Q1 2023.
• Historically, Receivables - Net has averaged $229444.4 across 5 years, with a median of $248500.0 in 2025.
• The sharpest annual moves came in 2023 and 2024: Receivables - Net tumbled 66.07% in 2023, then soared 600.0% in 2024.
• Over 5 years, Receivables - Net stood at $82000.0 in 2022, then jumped by 350.0% to $369000.0 in 2023, then sank by 36.04% to $236000.0 in 2024, then increased by 9.32% to $258000.0 in 2025, then retreated by 5.43% to $244000.0 in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $244000.0, $301000.0, and $258000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.